Abstract: Provided herein are 2?-fucosyllactose compounds and methods of using such for treating inflammatory bowel diseases (IBD) (e.g., Crohn's disease (CD) or ulcerative colitis (UC)) or alleviating or reducing the risk of relapse in IBD.

Abstract: Diagnostic methods for assessing risk of or presence of inflammatory bowel disease in a patient based on glycosyltransferase or histo-blood group antigen signatures or a combination thereof. Also disclosed herein are prognostic methods for monitoring inflammatory bowel disease progression in a patient.

Abstract: Provided herein are 2?-fucosyllactose compounds and methods of using such for treating inflammatory bowel diseases (IBD) (e.g.

Abstract: Diagnostic methods for assessing risk of or presence of inflammatory bowel disease in a patient based on glycosyltransferase or histo-blood group antigen signatures or a combination thereof. Also disclosed herein are prognostic methods for monitoring inflammatory bowel disease progression in a patient.

Abstract: Described are methods and compositions for evaluating the relapse risk n subjects having an inflammatory bowel disease (IBD). Some embodiments include selecting a treatment for an evaluated IBD relapse risk in a subject.

Abstract: Described are methods and compositions for evaluating the relapse risk n subjects having an inflammatory bowel disease (IBD). Some embodiments include selecting a treatment for an evaluated IBD relapse risk in a subject.

Abstract: Diagnostic methods for assessing risk of or presence of inflammatory bowel disease in a patient based on glycosyltransferase or histo-blood group antigen signatures or a combination thereof. Also disclosed herein are prognostic methods for monitoring inflammatory bowel disease progression in a patient.

Abstract: Disclosed are methods for classifying individuals having or suspected of having an inflammatory bowel disease, such as Crohn's Disease or Ulcerative Colitis, as ‘responders’ or ‘non-responders’ to first-line treatment, generally comprising the steps of a) obtaining a biological sample from the individual, b) isolating mRNA from the biological sample c) determining a gene expression profile from the biological sample; and d) comparing the gene expression profile of the individual to a reference gene expression profile or other suitable control such that changes in expression can be used to stratify individuals and predict efficacy of first-line therapy. A gene expression system is further provided for carrying out these methods.

Abstract: Disclosed are methods for classifying individuals having or suspected of having an inflammatory bowel disease, such as Crohn's Disease or Ulcerative Colitis, as “responders” or “non-responders” to first-line treatment, generally comprising the steps of a) obtaining, a biological sample from the individual, b) isolating mRNA from the biological sample c) determining a gene expression profile from the biological sample; and d) comparing the gene expression profile of the individual to a reference gene expression profile or other suitable control such that changes in expression can be used to stratify individuals and predict efficacy of first-line therapy. A gene expression system is further provided for carrying out these methods.

Abstract: Disclosed are novel biomarkers and methods related to diagnostic tests for the detection and characterization of inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. In particular, the instant invention relates to novel biomarkers and methods of using such biomarkers to predict disease behavior and severity, to differentiate among disease types, and to optimize selection of treatment options in individuals suspected of having an inflammatory bowel disease.